Patheon has signed a technology transfer agreement with Dendreon Corporation for commercial supply of proprietary density gradient solutions required during the manufacturing process for Provenge. The first autologous cellular immunotherapy to be approved by the FDA, Provenge is indicated for the treatment of asymptomatic or minimally symptomatic castrate resistant (hormone refractory) prostate cancer. “We are very excited that Dendreon has chosen Patheon to help them bring to market th...